Fresh analysis suggests that people who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds far faster than those who stop traditional diet and exercise programs.
Published data in a leading health publication shows that while obese people frequently drop substantial amounts of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"Users using these drugs need to be aware of the risk of rapid weight regain when the therapy concludes," warns expert Dr. Susan Jebb.
Such speed of recovery means a reversion to starting weight in about one and a half years.
Weighing Therapies
The analysis, which looked at 37 of trials involving thousands of participants, compared the effects of these new drugs with conventional dieting.
The team point out that people who lose weight through dieting usually have a less rapid creep back—around 100 grams monthly—after stopping.
The Reason for the Rapid Rebound
Experts believe the mode of action of the drugs explains the amplified rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate hunger.
"Long-term administration of the hormone levels far above than the body's typical production might result in the body to produce less of its endogenous GLP-1, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication leads to hunger is uncontrolled, making excessive eating a significant risk."
An Ongoing Disease?
The NHS advise the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Many experts say that, given the high risk of weight regain, the treatment is often life-long.
This view is echoed by drug manufacturers, who say that the results "highlight the long-term nature of obesity," akin to managing diseases like diabetes.
User Testimonies
People who have discontinued the jabs explain a intense return of hunger.
"It was like something that goes on and you become ravenous," described one woman.
This difficulty is worsened if patients have not developed lasting lifestyle or habit changes during treatment.
Growing Use
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is higher among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Finally, experts emphasize that while the jabs are potent tools for shedding pounds, they are not a permanent fix and maintained weight loss relies on integrated behavioural changes.